- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02500524
Cocamide DEA vs Permethrin for Head Lice
A Randomised, Controlled, Assessor-blind, Parallel Group Clinical Trial to Assess the Efficacy, Safety and Acceptability of a Surfactant Based Lotion and a Permethrin Creme Rinse in the Treatment of Head Lice
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A formulation of cocamide diethanolamine (DEA) surfactant was previously reported as showing efficacy to eliminate head louse infestation. This study has been designed to test those data using a new formulation of 10% cocamide DEA in an aqueous basis in comparison with the standard of care product 1% permethrin creme rinse. It is believed that surfactants like cocamide DEA are capable of eliminating lice resistant to conventional insecticides.
A planned total of 120 patients who, following examination, are found to suffer from active head lice infestation will be recruited to the trial. The patient will be treated with the appropriate product according to the randomization code from a pre-prepared listing in balanced blocks of 12.
10% Cocamide DEA is applied directly to dry hair and is washed off with shampoo after 60 minutes. Permethrin 1% creme rinse is applied to shampooed and towel dried hair and left in situ for 10 minutes, then rinsed off with clean water. Treatments will be applied by experienced investigators throughout the study. Assessments will be made by other investigators unaware of the treatment regimen used.
After treatment (day 0), follow up assessments will be performed on days 4, 7,10 then again at day 14 after which they will leave the study. Any adverse events or side effects from the treatments will be monitored during the study.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Cambridge, United Kingdom, CB25 9AU
- Medical Entomology Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients over the age of 4 who are found to have a head lice infection.
- Patients who give written informed consent or, if the patient is under 16 years of age, whose guardian gives written informed consent to participate in the study.
- Available for the duration of study i.e. 15 days.
Exclusion Criteria:
- Patients with a known sensitivity to pyrethroid, organophosphate, and/or carbamate insecticides, sensitivity to chrysanthemums and/or known sensitivity to paraben preservatives.
- Patients who have been treated with other head lice products within the last 4 weeks.
- Patients who have undergone a course of antibiotic treatment within the last 4 weeks.
- Patients who have any persistent skin disorder of the scalp (i.e. eczema, chronic dermatitis, psoriasis).
- Patients with asthma
- Patients whose hair has been bleached, colour treated or permed within the last 4 weeks.
- Pregnant or nursing mothers.
- Patients who have participated in another clinical trial within 1 month prior to entry to this study.
- Patients who have already participated in this clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 10% Cocamide diethanolamine
10% Cocamide DEA aqueous lotion is applied directly to dry hair on a single occasion and is washed off with shampoo after 60 minutes.
|
Topical lotion
Other Names:
|
|
Active Comparator: 1% permethrin creme rinse
1% permethrin creme rinse is applied to shampooed and towel dried hair on a single occasion and left in situ for 10 minutes, then rinsed off with clean water.
|
Topical creme rinse
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Elimination of infestation
Time Frame: 14 days
|
No evidence of active head lice infestation 14 days after enrolment.
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The number of participants with treatment related adverse events as a measure of safety
Time Frame: 14 days
|
No treatment related adverse events following treatment
|
14 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ian F Burgess, Medical Entomology Centre
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTRL01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediculosis Capitis
-
South Florida Family Health and Research CentersCompleted
-
ParaPRO LLCCompletedPediculosis Capitis (Head Lice)United States
-
ParaPRO LLCCompletedHead Lice | Pediculosis CapitisUnited States
-
ParaPRO LLCCompletedPediculosis Capitis (Head Lice)United States
-
ParaPRO LLCCompleted
-
Oystershell NVCompletedHead Lice | Pediculosis CapitisUnited States
-
Oystershell NVRecruitingHead Lice | Pediculosis CapitisUnited States
-
United LaboratoriesCompletedPediculosis CapitisPhilippines
-
Alliance PharmaceuticalsSouth Florida Family Health and Research CentersCompletedHead Lice | Lice Infestations | Pediculosis CapitisUnited States
-
Infectopharm Arzneimittel GmbHRecruitingPediculosis Capitis | Head Lice Infestation | LiceGermany
Clinical Trials on Cocamide diethanolamine
-
Medical Entomology CentreRiemann a/sTerminatedPediculosis | Head Louse Infestation
-
United TherapeuticsTerminatedSystemic SclerosisUnited States, Canada, United Kingdom
-
United TherapeuticsCompletedPulmonary Arterial HypertensionUnited States
-
United TherapeuticsCompletedSystemic SclerosisUnited States
-
United TherapeuticsTerminatedPulmonary Hypertension Associated With HFpEFUnited States
-
United TherapeuticsCompletedPulmonary Arterial Hypertension | Renal DysfunctionUnited States
-
United TherapeuticsCompletedPulmonary Arterial HypertensionUnited States
-
United TherapeuticsCompletedPulmonary Arterial HypertensionUnited States
-
United TherapeuticsCompletedPulmonary HypertensionUnited States
-
United TherapeuticsCompletedPulmonary Arterial HypertensionUnited States, Canada, India, United Kingdom, Spain, Israel, Australia, Belgium, France, Austria, China, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Sweden